| Applications: |
CLIA |
| Reactivity: |
Human |
| Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
| Sensitivity: |
37.5pg/mL |
| Detection Limit: |
62.5~4000pg/mL |
| Short Description: |
This human HLA-E kit is a highly sensitive in-vitro chemiluminescent immunoassay for the measurement of trace amounts of analytes. |
| Storage Instruction: |
If unopened the kit may be stored at 2-8°C for up to 1 month. If the kit will not be used within 1 month, store the components separately, according to the component table in the manual. |
| Assay Time: |
3.5h |
| Detection: |
Chemiluminescence |
| Gene Symbol: |
HLA-E |
| Gene ID: |
3133 |
| Uniprot ID: |
HLAE_HUMAN |
| Specificity: |
This kit recognizes Human MHCE/HLA-E in samples. No significant cross-reactivity or interference between Human MHCE/HLA-E and analogues was observed. |
| Sample Type: |
Serum, plasma and other biological fluids |
| Tissue Specificity | Expressed in secretory endometrial cells during pregnancy (at protein level). The expression in nonlymphoid tissues is restricted to endothelial cells from all types of vessels, including arteries, veins, capillaries, and lymphatics (at protein level). In lymphoid organs, it is mainly expressed in endothelial venules, B and T cells, monocytes, macrophages, NK cells and megakaryocytes (at protein level). |
| Post Translational Modifications | N-glycosylated. The soluble form (sHLA-E) can be partly produced by proteolytic cleavage at the cell surface (shedding) by a matrix metalloproteinase. Alternative splicing is also suggested as a mechanism for generation of sHLA-E, although it remains to be proved. |
| Function | Non-classical major histocompatibility class Ib molecule involved in immune self-nonself discrimination. In complex with B2M/beta-2-microglobulin binds nonamer self-peptides derived from the signal sequence of classical MHC class Ia molecules (VL9 peptides - VMAPRTV/LL/V/I/FL). Peptide-bound HLA-E-B2M heterotrimeric complex primarily functions as a ligand for natural killer (NK) cell inhibitory receptor KLRD1-KLRC1, enabling NK cells to monitor the expression of other MHC class I molecules in healthy cells and to tolerate self. Upon cellular stress, preferentially binds signal sequence-derived peptides from stress-induced chaperones and is no longer recognized by NK cell inhibitory receptor KLRD1-KLRC1, resulting in impaired protection from NK cells. Binds signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules and acts as a ligand for NK cell activating receptor KLRD1-KLRC2, likely playing a role in the generation and effector functions of adaptive NK cells and in maternal-fetal tolerance during pregnancy. Besides self-peptides, can also bind and present pathogen-derived peptides conformationally similar to VL9 peptides to alpha-beta T cell receptor (TCR) on unconventional CD8-positive cytotoxic T cells, ultimately triggering antimicrobial immune response. Presents HIV gag peptides (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes) predominantly to CD8-positive T cell clones expressing a TRAV17-containing TCR, triggering HLA-E-restricted T cell responses. Presents mycobacterial peptides to HLA-E-restricted CD8-positive T cells eliciting both cytotoxic and immunoregulatory functions. (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells. (Microbial infection) May bind HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition. (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells. Binds SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening of antiviral immune surveillance. |
| Protein Name | Hla Class I Histocompatibility Antigen - Alpha Chain EMhc Class I Antigen E Cleaved Into - Soluble Hla Class I Histocompatibility Antigen - Alpha Chain EShla-E |
| Database Links | Reactome: R-HSA-1236974Reactome: R-HSA-1236977Reactome: R-HSA-198933Reactome: R-HSA-2172127Reactome: R-HSA-2424491Reactome: R-HSA-877300Reactome: R-HSA-909733Reactome: R-HSA-9705671Reactome: R-HSA-983170 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinGolgi Apparatus MembraneSoluble Hla Class I Histocompatibility AntigenAlpha Chain E: Secreted |
| Alternative CLIA Names | Hla Class I Histocompatibility Antigen - Alpha Chain E CLIA kitMhc Class I Antigen E Cleaved Into - Soluble Hla Class I Histocompatibility Antigen - Alpha Chain E CLIA kitShla-E CLIA kitHLA-E CLIA kitHLA-6.2 CLIA kitHLAE CLIA kit |
| Specificity | This kit recognizes Human MHCE/HLA-E in samples. No significant cross-reactivity or interference between Human MHCE/HLA-E and analogues was observed. |
| Reproducibility | Both intra-CV and inter-CV are |
Information sourced from Uniprot.org
| Item | Specifications | Storage |
| Micro CLIA Plate (Dismountable) | 96T: 8 wells ×12 strips strips | -20℃, 6 months |
| Reference Standard | 96T: 2 vials 48T: 1 vial | -20℃, 6 months |
| Concentrated Biotinylated Detection Ab (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃, 6 months |
| Concentrated HRP Conjugate (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃ (Protect from light), 6 months |
| Reference Standard & Sample Diluent | 1 vial, 20 mL | 2-8°C, 6 months |
| Biotinylated Detection Ab Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| HRP Conjugate Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| Concentrated Wash Buffer (25×) | 1 vial, 30 mL | 2-8°C, 6 months |
| Substrate Reagent A | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Substrate Reagent B | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Plate Sealer | 5 pieces | |
| Manual | 1 copy | |
| Certificate of Analysis | 1 copy | |
| Sample Type | Range (%) | Average Recovery (%) |
| Serum(n=8) | 97-111 | 102 |
| EDTA plasma(n=8) | 102-114 | 107 |
| Cell culture media(n=8) | 85-96 | 90 |
| | Intra-assay Precision | Intra-assay Precision | Intra-assay Precision | Inter-assay Precision | Inter-assay Precision | Inter-assay Precision |
| Sample | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 |
| n | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
| Mean (pg/mL) | 204.82 | 349.57 | 1715.65 | 196.52 | 361.28 | 1865.04 |
| Standard deviation | 24.64 | 35.13 | 178.94 | 23.05 | 27.06 | 146.22 |
| CV (%) | 12.03 | 10.05 | 10.43 | 11.73 | 7.49 | 7.84 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
